Top

Published in:

01-06-2008

Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias

Authors: Danilo Perrotti, Paolo Neviani

Published in: Cancer and Metastasis Reviews | Issue 2/2008

Abstract

Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine phosphatases and is involved in the regulation of cell homeostasis through the negative regulation of signaling pathways initiated by protein kinases. As several cancers are characterized by the aberrant activity of oncogenic kinases, it was not surprising that a phosphatase like PP2A has progressively been considered as a potential tumor suppressor. Indeed, multiple solid tumors (e.g. melanomas, colorectal carcinomas, lung and breast cancers) present with genetic and/or functional inactivation of different PP2A subunits and, therefore, loss of PP2A phosphatase activity towards certain substrates. Likewise, impaired PP2A phosphatase activity has been linked to B-cell chronic lymphocytic leukemia, Philadelphia-chromosome positive acute lymphoblastic leukemia and blast crisis chronic myelogenous leukemia. Remarkably, drugs such as forskolin, 1,9-dideoxy-forskolin and FTY720 which lead to PP2A activation effectively antagonize leukemogenesis in both in vitro and in vivo models of these cancers. Thus, PP2A is now in the spotlight as a highly promising drugable target for the development of a new series of anticancer agents potentially capable of overcoming drug-resistance induced in patients by continuous exposure to kinase inhibitor monotherapy. Herein, we review current knowledge of PP2A biology and function with particular emphasis on its tumor suppressor activity and possible therapeutic implications in cancer.

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70.PubMedCrossRef

Todd, R., & Wong, D. T. (1999). Oncogenes. Anticancer Research, 19(6A), 4729–4746.PubMed

Sherr, C. J. (2004). Principles of tumor suppression. Cell, 116(2), 235–246.PubMedCrossRef

Yokota, J. (2000). Tumor progression and metastasis. Carcinogenesis, 21(3), 497–503.PubMedCrossRef

Hunter, T. (1995). Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell, 80(2), 225–236.PubMedCrossRef

Levine, A. J., & Broach, J. R. (1995). Oncogenes and cell proliferation. Current Opinion in Genetics & Development, 5(1), 1–4.CrossRef

Calabretta, B., & Perrotti, D. (2004). The biology of CML blast crisis. Blood, 103(11), 4010–4022.PubMedCrossRef

Westbrook, C. A., Hooberman, A. L., Spino, C., Dodge, R. K., Larson, R. A., Davey, F., et al. (1992). Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study (8762). Blood, 80(12), 2983–2990.PubMed

Tonks, N. K. (2006). Protein tyrosine phosphatases: From genes, to function, to disease. Nature Reviews Molecular Cell Biology, 7(11), 833–846.PubMedCrossRef

10.

Janssens, V., Goris, J., & Van Hoof, C. (2005). PP2A: the expected tumor suppressor. Current Opinion in Genetics & Development, 15(1), 34–41.CrossRef

11.

Perrotti, D., & Neviani, P. (2006). ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. British Journal of Cancer, 95(7), 775–781.PubMedCrossRef

12.

Janssens, V., & Goris, J. (2001). Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochemical Journal, 353(Pt 3), 417–439.PubMedCrossRef

13.

Schonthal, A. H. (2001). Role of serine/threonine protein phosphatase 2A in cancer. Cancer Letter, 170(1), 1–13.CrossRef

14.

Lechward, K., Awotunde, O. S., Swiatek, W., & Muszynska, G. (2001). Protein phosphatase 2A: Variety of forms and diversity of functions. Acta Biochimica Polonica, 48(4), 921–933.PubMed

15.

Healy, A. M., Zolnierowicz, S., Stapleton, A. E., Goebl, M., DePaoli-Roach, A. A., & Pringle, J. R. (1991). CDC55, a Saccharomyces cerevisiae gene involved in cellular morphogenesis: Identification, characterization, and homology to the B subunit of mammalian type 2A protein phosphatase. Molecular and Cellular Biology, 11(11), 5767–5780.PubMed

16.

Mayer-Jaekel, R. E., Ohkura, H., Gomes, R., Sunkel, C. E., Baumgartner, S., Hemmings, B. A., et al. (1993). The 55 kd regulatory subunit of Drosophila protein phosphatase 2A is required for anaphase. Cell, 72(4), 621–633.PubMedCrossRef

17.

Schild, A., Schmidt, K., Lim, Y. A., Ke, Y., Ittner, L. M., Hemmings, B. A., et al. (2006). Altered levels of PP2A regulatory B/PR55 isoforms indicate role in neuronal differentiation. International Journal of Developmental Neuroscience, 24(7), 437–443.PubMedCrossRef

18.

Okamoto, K., Li, H., Jensen, M. R., Zhang, T., Taya, Y., Thorgeirsson, S. S., et al. (2002). Cyclin G recruits PP2A to dephosphorylate Mdm2. Molecular Cell, 9(4), 761–771.PubMedCrossRef

19.

Voorhoeve, P. M., Hijmans, E. M., & Bernards, R. (1999). Functional interaction between a novel protein phosphatase 2A regulatory subunit, PR59, and the retinoblastoma-related p107 protein. Oncogene, 18(2), 515–524.PubMedCrossRef

20.

Sontag, E. (2001). Protein phosphatase 2A: The Trojan Horse of cellular signaling. Cell Signal, 13(1), 7–16.PubMedCrossRef

21.

Sontag, E., Fedorov, S., Kamibayashi, C., Robbins, D., Cobb, M., & Mumby, M. (1993). The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell, 75(5), 887–897.PubMedCrossRef

22.

Lee, T. H., Turck, C., & Kirschner, M. W. (1994). Inhibition of cdc2 activation by INH/PP2A. Molecular Biology of the Cell, 5(3), 323–338.PubMed

23.

Van Hoof, C., & Goris, J. (2003). Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. Biochimica et Biophysica Acta, 1640(2–3), 97–104.PubMed

24.

Yang, J., Fan, G. H., Wadzinski, B. E., Sakurai, H., & Richmond, A. (2001). Protein phosphatase 2A interacts with and directly dephosphorylates RelA. Journal of Biological Chemistry, 276(51), 47828–47833.PubMed

25.

Ivaska, J., Nissinen, L., Immonen, N., Eriksson, J. E., Kahari, V. M., & Heino, J. (2002). Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Molecular and Cellular Biology, 22(5), 1352–1359.PubMedCrossRef

26.

Peterson, R. T., Desai, B. N., Hardwick, J. S., & Schreiber, S. L. (1999). Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proceedings of the National Academy of Sciences of the United States of America, 96(8), 4438–4442.PubMedCrossRef

27.

Montagne, J., Stewart, M. J., Stocker, H., Hafen, E., Kozma, S. C., & Thomas, G. (1999). Drosophila S6 kinase: a regulator of cell size. Science, 285(5436), 2126–2129.PubMedCrossRef

28.

Hornstein, E., Tang, H., & Meyuhas, O. (2001). Mitogenic and nutritional signals are transduced into translational efficiency of TOP mRNAs. Cold Spring Harbor Symposia on Quantitative Biology, 66, 477–484.PubMedCrossRef

29.

Li, X., Yost, H. J., Virshup, D. M., & Seeling, J. M. (2001). Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus. European Molecular Biology Organization Journal, 20(15), 4122–4131.

30.

Sontag, J. M., & Sontag, E. (2006). Regulation of cell adhesion by PP2A and SV40 small tumor antigen: An important link to cell transformation. Cellular and Molecular Life Sciences, 63(24), 2979–2991.PubMedCrossRef

31.

Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., et al. (2006). Structure of the protein phosphatase 2A holoenzyme. Cell, 127(6), 1239–1251.PubMedCrossRef

32.

Longin, S., Zwaenepoel, K., Louis, J. V., Dilworth, S., Goris, J., & Janssens, V. (2007). Selection of protein phosphatase 2A regulatory subunits is mediated by the C-terminus of the catalytic subunit. Journal of Biological Chemistry, 282, 26971–26980.PubMedCrossRef

33.

Li, M., & Damuni, Z. (1998). I1PP2A and I2PP2A. Two potent protein phosphatase 2A-specific inhibitor proteins. Methods in Molecular Biology, 93, 59–66.PubMed

34.

Kovacech, B., Kontsekova, E., Zilka, N., Novak, P., Skrabana, R., Filipcik, P., et al. (2007). A novel monoclonal antibody DC63 reveals that inhibitor 1 of protein phosphatase 2A is preferentially nuclearly localised in human brain. Federation of European Biochemical Societies Letters, 581(4), 617–622.PubMed

35.

Li, M., Makkinje, A., & Damuni, Z. (1996). The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. Journal of Biological Chemistry, 271(19), 11059–11062.PubMedCrossRef

36.

Adachi, Y., Pavlakis, G. N., & Copeland, T. D. (1994). Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. Journal of Biological Chemistry, 269(3), 2258–2262.PubMed

37.

Adler, H. T., Nallaseth, F. S., Walter, G., & Tkachuk, D. C. (1997). HRX leukemic fusion proteins form a heterocomplex with the leukemia-associated protein SET and protein phosphatase 2A. Journal of Biological Chemistry, 272(45), 28407–28414.PubMedCrossRef

38.

Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., et al. (2005). The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 8(5), 355–368.PubMedCrossRef

39.

Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M., Blaser, B. W., et al. (2007). FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. Journal of Clinical Investigation, 117(9), 2408–2421.PubMedCrossRef

40.

Trotta, R., Ciarlariello, D., Col, J. D., Allard 2nd, J., Neviani, P., Santhanam, R., et al. (2007). The PP2A inhibitor SET regulates natural killer cell IFN-{gamma} production. Journal of Experimental Medicine, 204, 2397–2405.PubMedCrossRef

41.

Bialojan, C., & Takai, A. (1988). Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochemical Journal, 256(1), 283–290.PubMed

42.

Arroyo, J. D., & Hahn, W. C. (2005). Involvement of PP2A in viral and cellular transformation. Oncogene, 24(52), 7746–7755.PubMedCrossRef

43.

Junttila, M. R., Puustinen, P., Niemela, M., Ahola, R., Arnold, H., Bottzauw, T., et al. (2007). CIP2A inhibits PP2A in human malignancies. Cell, 130(1), 51–62.PubMedCrossRef

44.

Sablina, A. A., Chen, W., Arroyo, J. D., Corral, L., Hector, M., Bulmer, S. E., et al. (2007). The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell, 129(5), 969–982.PubMedCrossRef

45.

Francia, G., Poulsom, R., Hanby, A. M., Mitchell, S. D., Williams, G., McKee, P., et al. (1999). Identification by differential display of a protein phosphatase-2A regulatory subunit preferentially expressed in malignant melanoma cells. International Journal of Cancer, 82(5), 709–713.CrossRef

46.

Ito, A., Kataoka, T. R., Watanabe, M., Nishiyama, K., Mazaki, Y., Sabe, H., et al. (2000). A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation. European Molecular Biology Organization Journal, 19(4), 562–571.

47.

Chen, W., Possemato, R., Campbell, K. T., Plattner, C. A., Pallas, D. C., & Hahn, W. C. (2004). Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell, 5(2), 127–136.PubMedCrossRef

48.

Ito, A., Koma, Y., Watabe, K., Nagano, T., Endo, Y., Nojima, H., et al. (2003). A truncated isoform of the protein phosphatase 2A B56gamma regulatory subunit may promote genetic instability and cause tumor progression. American Journal of Pathology, 162(1), 81–91.PubMed

49.

Silverstein, A. M., Barrow, C. A., Davis, A. J., & Mumby, M. C. (2002). Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proceedings of the National Academy of Sciences of the United States of America, 99(7), 4221–4226.PubMedCrossRef

50.

Li, X., Scuderi, A., Letsou, A., & Virshup, D. M. (2002). B56-associated protein phosphatase 2A is required for survival and protects from apoptosis in Drosophila melanogaster. Molecular and Cellular Biology, 22(11), 3674–3684.PubMedCrossRef

51.

Calin, G. A., di Iasio, M. G., Caprini, E., Vorechovsky, I., Natali, P. G., Sozzi, G., et al. (2000). Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene, 19(9), 1191–1195.PubMedCrossRef

52.

Ruediger, R., Pham, H. T., & Walter, G. (2001). Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene, 20(15), 1892–1899.PubMedCrossRef

53.

Takagi, Y., Futamura, M., Yamaguchi, K., Aoki, S., Takahashi, T., & Saji, S. (2000). Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut, 47(2), 268–2671.PubMedCrossRef

54.

Wang, S. S., Esplin, E. D., Li, J. L., Huang, L., Gazdar, A., Minna, J., et al. (1998). Alterations of the PPP2R1B gene in human lung and colon cancer. Science, 282(5387), 284–287.PubMedCrossRef

55.

Esplin, E. D., Ramos, P., Martinez, B., Tomlinson, G. E., Mumby, M. C., & Evans, G. A. (2006). The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function. Genes Chromosomes Cancer, 45(2), 182–190.PubMedCrossRef

56.

Baysal, B. E., Willett-Brozick, J. E., Taschner, P. E., Dauwerse, J. G., Devilee, P., & Devlin, B. (2001). A high-resolution integrated map spanning the SDHD gene at 11q23: A 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor region. European Journal of Human Genetics, 9(2), 121–129.PubMedCrossRef

57.

Camonis, J. H., & White, M. A. (2005). Ral GTPases: corrupting the exocyst in cancer cells. Trends in Cell Biology, 15(6), 327–332.PubMedCrossRef

58.

Tamaki, M., Goi, T., Hirono, Y., Katayama, K., & Yamaguchi, A. (2004). PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers. Oncology Reports, 11(3), 655–659.PubMed

59.

Chen, W., Arroyo, J. D., Timmons, J. C., Possemato, R., & Hahn, W. C. (2005). Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Research, 65(18), 8183–8192.PubMedCrossRef

60.

Trotman, L. C., Alimonti, A., Scaglioni, P. P., Koutcher, J. A., Cordon-Cardo, C., & Pandolfi, P. P. (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature, 441(7092), 523–527.PubMedCrossRef

61.

Soo Hoo, L., Zhang, J. Y., & Chan, E. K. (2002). Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer. Oncogene, 21(32), 5006–5015.PubMedCrossRef

62.

Arnold, H. K., & Sears, R. C. (2006). Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Molecular and Cellular Biology, 26(7), 2832–2844.PubMedCrossRef

63.

Sears, R. C. (2004). The life cycle of C-myc: from synthesis to degradation. Cell Cycle, 3(9), 1133–1137.PubMed

64.

Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., et al. (2004). A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature Cell Biology, 6(4), 308–318.PubMedCrossRef

65.

Escamilla-Powers, J. R., & Sears, R. C. (2007). A conserved pathway that controls c-Myc protein stability through opposing phosphorylation events occurs in yeast. Journal of Biological Chemistry, 282(8), 5432–5442.PubMedCrossRef

66.

Kalla, C., Scheuermann, M. O., Kube, I., Schlotter, M., Mertens, D., Dohner, H., et al. (2007). Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B. European Journal of Cancer, 43(8), 1328–1335.PubMedCrossRef

67.

Dohner, H., Stilgenbauer, S., James, M. R., Benner, A., Weilguni, T., Bentz, M., et al. (1997). 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood, 89(7), 2516–2522.PubMed

68.

Zhu, Y., Loukola, A., Monni, O., Kuokkanen, K., Franssila, K., Elonen, E., et al. (2001). PPP2R1B gene in chronic lymphocytic leukemias and mantle cell lymphomas. Leukaemia and Lymphoma, 41(1–2), 177–183.CrossRef

69.

Liu, Q., Zhao, X., Frissora, F., Ma, Y., Santhanam, R., Jarjoura, D., et al. (2008). FTY720 demonstrates promising pre-clinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood, 111, 275–284.PubMedCrossRef

70.

Dumont, F. J. (2005). Fingolimod. Mitsubishi Pharma/Novartis. IDrugs, 8(3), 236–253.PubMed

71.

Virley, D. J. (2005). Developing therapeutics for the treatment of multiple sclerosis. NeuroRx, 2(4), 638–649.PubMedCrossRef

72.

Budde, K., Schmouder, R. L., Brunkhorst, R., Nashan, B., Lucker, P. W., Mayer, T., et al. (2002). First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. Journal of the American Society of Nephrology, 13(4), 1073–1083.PubMed

73.

Skerjanec, A., Tedesco, H., Neumayer, H. H., Cole, E., Budde, K., Hsu, C. H., et al. (2005). FTY720, a novel immunomodulator in de novo kidney transplant patients: Pharmacokinetics and exposure–response relationship. Journal of Clinical Pharmacology, 45(11), 1268–1278.PubMedCrossRef

74.

Brinkmann, V. (2004). FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Medical Journal, 45(6), 991–997.PubMed

75.

Kovarik, J. M., Schmouder, R., Barilla, D., Riviere, G. J., Wang, Y., & Hunt, T. (2004). Multiple-dose FTY720: Tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. Journal of Clinical Pharmacology, 44(5), 532–537.PubMedCrossRef

76.

Iervolino, A., Santilli, G., Trotta, R., Guerzoni, C., Cesi, V., Bergamaschi, A., et al. (2002). hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Molecular and Cellular Biology, 22(7), 2255–2266.PubMedCrossRef

77.

Perrotti, D., & Neviani, P. (2007). From mRNA metabolism to cancer therapy: Chronic myelogenous leukemia shows the way. Clinical Cancer Research, 13(6), 1638–1642.PubMedCrossRef

78.

Sato, S., Fujita, N., & Tsuruo, T. (2000). Modulation of Akt kinase activity by binding to Hsp90. Proceedings of the National Academy of Sciences of the United States of America, 97(20), 10832–10837.PubMedCrossRef

79.

Yokoyama, N., Reich, N. C., & Miller, W. T. (2001). Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway. Journal of Interferon and Cytokine Research, 21(6), 369–378.PubMedCrossRef

80.

Chiang, C. W., Kanies, C., Kim, K. W., Fang, W. B., Parkhurst, C., Xie, M., et al. (2003). Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Molecular and Cellular Biology, 23(18), 6350–6362.PubMedCrossRef

81.

Gomez, N., & Cohen, P. (1991). Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases. Nature, 353(6340), 170–173.PubMedCrossRef

82.

Avni, D., Yang, H., Martelli, F., Hofmann, F., ElShamy, W. M., Ganesan, S., et al. (2003). Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Molecular Cell, 12(3), 735–746.PubMedCrossRef

83.

Cortez, D., Reuther, G., & Pendergast, A. M. (1997). The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene, 15(19), 2333–2342.PubMedCrossRef

84.

Feschenko, M. S., Stevenson, E., Nairn, A. C., & Sweadner, K. J. (2002). A novel cAMP-stimulated pathway in protein phosphatase 2A activation. Journal of Pharmacology and Experimental Therapeutics, 302(1), 111–118.PubMedCrossRef

85.

Matsuoka, Y., Nagahara, Y., Ikekita, M., & Shinomiya, T. (2003). A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. British Journal of Pharmacology, 138(7), 1303–1312.PubMedCrossRef

86.

Liedtke, M., Pandey, P., Kumar, S., Kharbanda, S., & Kufe, D. (1998). Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. Oncogene, 17(15), 1889–1892.PubMedCrossRef

87.

Lim, Y. M., Wong, S., Lau, G., Witte, O. N., & Colicelli, J. (2000). BCR/ABL inhibition by an escort/phosphatase fusion protein. Proceedings of the National Academy of Sciences of the United States of America, 97(22), 12233–12238.PubMedCrossRef

88.

Chen, P., Levis, M., Brown, P., Kim, K. T., Allebach, J., & Small, D. (2005). FLT3/ITD mutation signaling includes suppression of SHP-1. Journal of Biological Chemistry, 280(7), 5361–5369.PubMedCrossRef

89.

Wu, C., Guan, Q., Wang, Y., Zhao, Z. J., & Zhou, G. W. (2003). SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. Journal of Cellular Biochemistry, 90(5), 1026–1037.PubMedCrossRef

90.

Wu, C., Sun, M., Liu, L., & Zhou, G. W. (2003). The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene, 306, 1–12.PubMedCrossRef

91.

Ding, X., & Staudinger, J. L. (2005). Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway. Journal of Pharmacology and Experimental Therapeutics, 312(2), 849–856.PubMedCrossRef

92.

Seamon, K., & Daly, J. W. (1981). Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. Journal of Biological Chemistry, 256(19), 9799–9801.PubMed

Title: Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias
Authors: Danilo Perrotti
Paolo Neviani
Publication date: 01-06-2008
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9119-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Targeted therapy for oesophageal cancer: an overview

Preface

A tumor suppressor role for PP2A-B56α through negative regulation of c-Myc and other key oncoproteins

SV40 small T antigen and PP2A phosphatase in cell transformation

Dual-specificity MAP kinase phosphatases (MKPs) and cancer

Biography - Stephen M. Keyse

Keynote webinar | Spotlight on antibody–drug conjugates in cancer